Production (Stage)
Xeris Biopharma Holdings, Inc.
XERS
$4.83
-$0.05-1.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -45.08M | -54.84M | -63.11M | -59.56M | -64.40M |
| Total Depreciation and Amortization | 12.55M | 12.63M | 12.75M | 12.98M | 13.19M |
| Total Amortization of Deferred Charges | 3.28M | 3.01M | 2.71M | 2.48M | 2.23M |
| Total Other Non-Cash Items | 14.96M | 11.04M | 7.00M | 8.90M | 5.86M |
| Change in Net Operating Assets | -12.43M | -8.82M | 9.17M | -2.59M | 1.93M |
| Cash from Operations | -26.71M | -36.98M | -31.49M | -37.79M | -41.19M |
| Capital Expenditure | -717.00K | -868.00K | -780.00K | -1.04M | -2.19M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 25.24M | 5.75M | 10.52M | 15.51M | 20.51M |
| Cash from Investing | 24.52M | 4.88M | 9.74M | 14.48M | 18.33M |
| Total Debt Issued | 0.00 | 50.00M | 50.00M | 50.00M | 50.00M |
| Total Debt Repaid | 0.00 | 0.00 | 0.00 | -11.83M | -- |
| Issuance of Common Stock | 6.14M | 1.73M | 1.17M | 1.17M | 1.04M |
| Repurchase of Common Stock | -8.30M | -3.73M | -3.62M | -3.61M | -3.58M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -11.83M | -13.02M | -1.19M | -13.02M |
| Cash from Financing | -2.16M | 36.17M | 34.54M | 34.55M | 34.44M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.35M | 4.07M | 12.79M | 11.23M | 11.58M |